Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MAGE-3.A1 Peptide Vaccine

Known as: HLA-A1-Restricted MAGE-3 Peptide Vaccine, MAGE-3.A1 
A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
We previously characterized the CTL response of a melanoma patient who experienced tumor regression following vaccination with an… Expand
  • figure 1
  • figure 2
  • table III
  • figure 3
Highly Cited
2008
Highly Cited
2008
Tumor regressions have been observed in a small proportion of melanoma patients vaccinated with a MAGE-A3 peptide presented by… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2006
2006
Gene MAGE-A3 encodes tumor-specific antigenic peptides recognized by T cells on many tumors. MAGE-A3 peptides presented by HLA… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2005
Highly Cited
2005
Melanoma patients have high frequencies of T cells directed against antigens of their tumor. The frequency of these antitumor T… Expand
  • figure 1
  • figure 2
  • table I
2005
2005
We describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2004
Highly Cited
2004
The cancer-germline gene MAGE-3 codes for tumor-specific antigens recognized on many tumors by T lymphocytes. A MAGE-3 antigen… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2003
Highly Cited
2003
We have analyzed the T cell responses of HLA-A1 metastatic melanoma patients with detectable disease, following vaccination with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
Vaccination with mature, monocyte-derived dendritic cells (DC) pulsed with the MAGE-3168–176 peptide, which is presented by HLA… Expand
  • figure 1
  • figure 2
Highly Cited
2001
Highly Cited
2001
Cell surface expression of HLA class I/peptide complexes on tumor cells is a key step in the generation of T‐cell‐based immune… Expand
Highly Cited
1999
Highly Cited
1999
Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE‐3.A1 peptide… Expand